A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and non-steroidal (anastrozole) aromatase inhibitors on biomarkers in post-menopausal women with hormone receptor positive locally advanced breast cancer (LABC)

被引：0
|
作者：
Freedman, O. [1 ]
Amir, E. [1 ]
Dranitsaris, G. [1 ]
Dowsett, M. [2 ]
Cole, D. E. C. [3 ]
Hanna, W. [4 ]
O'Malley, F. [5 ]
Folkerd, E. [2 ]
Verma, S. [4 ]
Clemons, M. J. [1 ]
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Royal Marsden Hosp, London SW3 6JJ, England
[3] Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada
[4] Odette Canc Ctr, Toronto, ON, Canada
[5] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70919-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：269 / 269
页数：1
相关论文
共 50 条
  • [21] Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)
    Mlineritsch, Brigitte
    Tausch, Christoph
    Singer, Christian
    Luschin-Ebengreuth, Gero
    Jakesz, Raimund
    Ploner, Ferdinand
    Stierer, Michael
    Melbinger, Elisabeth
    Menzel, Christian
    Urbania, Andrea
    Fridrik, Michael
    Steger, Guenther
    Wohlmuth, Peter
    Gnant, Michael
    Greil, Richard
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (01) : 203 - 213
  • [22] Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)
    Brigitte Mlineritsch
    Christoph Tausch
    Christian Singer
    Gero Luschin-Ebengreuth
    Raimund Jakesz
    Ferdinand Ploner
    Michael Stierer
    Elisabeth Melbinger
    Christian Menzel
    Andrea Urbania
    Michael Fridrik
    Günther Steger
    Peter Wohlmuth
    Michael Gnant
    Richard Greil
    Breast Cancer Research and Treatment, 2008, 112 : 203 - 213
  • [23] First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial
    Tripathy, Debu
    Sohn, Joohyuk
    Im, Seock-Ah
    Colleoni, Marco
    Franke, Fabio
    Bardia, Aditya
    Harbeck, Nadia
    Hurvitz, Sara
    Chow, Louis
    Lee, Keun Seok
    Campos-Gomez, Saul
    Vazquez, Rafael Villanueva
    Jung, Kyung Hae
    Carlson, Gary
    Hughes, Gareth
    Diaz-Padilla, Ivan
    Germa, Caroline
    Hirawat, Samit
    Lu, Yen-Shen
    CANCER RESEARCH, 2018, 78 (04)
  • [24] Safety of everolimus plus exemestane in elderly patients with Hormone-Receptor-Positive (HR+), HER2-locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors (NSAIs): BALLET (CRAD001YIC04)
    Neven, P.
    Generali, D.
    Ciruelos, E. M.
    Lang, I.
    Gavila, J. G.
    Bighin, C.
    Borms, M.
    Conte, P.
    Montemurro, F.
    Sartori, D.
    Lee, T. V.
    Camozzi, M.
    Lorizzo, K.
    Ocak, O.
    Jerusalem, G.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S282 - S282
  • [25] Randomized, controlled phase II trial of exemestane compared with medroxyprogesterone after nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer
    Wang, T.
    Huang, H.
    Zhang, S.
    Bian, L.
    Jiang, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
    Jerusalem, G.
    Mariani, G.
    Ciruelos, E. M.
    Martin, M.
    Tjan-Heijnen, V. C. G.
    Neven, P.
    Gavila, J. G.
    Michelotti, A.
    Montemurro, F.
    Generali, D.
    Simoncini, E.
    Lang, I.
    Mardiak, J.
    Naume, B.
    Camozzi, M.
    Lorizzo, K.
    Bianchetti, S.
    Conte, P.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1719 - 1725
  • [27] Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial
    Fullana, Bartomeu
    Morales, Serafin
    Petit, Anna
    Alay, Ania
    Verdaguer, Helena
    Climent, Fina
    Navarro-Perez, Valenti
    Cejuela, Monica
    Galvan, Patricia
    Guma, Anna
    Llombart-Cussac, Antonio
    Cordero, David
    Casanovas, Oriol
    Prat, Aleix
    Gil-Gil, Miguel
    Pernas, Sonia
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [28] Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis
    Tripathy, D.
    Campos-Gomez, S.
    Lu, Y-S
    Franke, F.
    Bardia, A.
    Wheatley-Price, P.
    Cruz, F. M.
    Hegg, R.
    Cardoso, F.
    Gaur, A.
    Kong, O.
    Diaz-Padilla, I.
    Miller, M.
    Hurvitz, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [29] A randomized phase II trial of toremifene (120 mg) versus fulvestrant ( 500 mg) after prior non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study)
    Nishimura, Reiki
    Yamamoto, Yutaka
    Narui, Kazutaka
    Kijima, Yuko
    Hozumi, Yasuo
    Ikeda, Masahiko
    Takao, Shintaro
    Ohtani, Shoichiro
    Iwase, Hirotaka
    CANCER RESEARCH, 2018, 78 (04)
  • [30] Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
    Moy, Beverly
    Neven, Patrick
    Lebrun, Fabienne
    Bellet, Meritxell
    Xu, Binghe
    Sarosiek, Tomasz
    Chow, Louis
    Goss, Paul
    Zacharchuk, Charles
    Leip, Eric
    Turnbull, Kathleen
    Bardy-Bouxin, Nathalie
    Duvillie, Ladan
    Lang, Istvan
    ONCOLOGIST, 2014, 19 (04): : 346 - 347
12345